HDV RNA Undetectability Rates During Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta May Be Assay Dependent
Elisabetta Degasperi: Advisory Board: AbbVie; Speaking and teaching: Gilead, MSD, AbbVie; Pietro Lampertico: Advisor and speaker bureau for Roche Pharma/Diagnostics, Gilead Sciences, Gsk, Abbvie, Janssen, Myr, Eiger, Antios, Aligos, Vir, Grifols, Altona, Roboscreen. Other authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Authors
- Sara Monico (ORCID: https://orcid.org/0000-0001-5359-850X)
- R. Soffredini
- Maria Paola Anolli (ORCID: https://orcid.org/0000-0001-6901-5575)
- Marta Borghi
- Dana Sambarino
- Elisabetta Degasperi (ORCID: https://orcid.org/0000-0002-9899-4669)
- F. Facchetti (ORCID: https://orcid.org/0000-0001-5252-4744)
- Sara Uceda Renteria
- Pietro Lampertico (ORCID: https://orcid.org/0000-0002-1026-7476)
- Annapaola Callegaro
Institutions
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Ospedale Maggiore (IT)
Publication Details
- Journal
- Liver International
- Published
- 2026-05-09
- DOI
- https://doi.org/10.1111/liv.70677
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00